
Episode 76
Biotech Hangout
00:00
Disappointing Results of F4 Cirrhosis Nash Study and Impact on Stock
The chapter discusses the disappointing results of a study on F4 cirrhosis Nash and the potential negative impact on the stock. They mention concerns about the timeline for a larger phase 3 study and the fear surrounding the F2-3 space.
Transcript
Play full episode